

INVESTIGATING THE MECHANISMS OF DRUG RESISTANCE IN CANCER CELLS

CHIRANJEEV SINGH¹, NAINA BHOYAR², DR. MONICA VERMA³

¹ASSISTANT PROFESSOR, DEPARTMENT OF PHARMACY, KALINGA UNIVERSITY, RAIPUR, INDIA.
ku.chiranjeevsingh@kalingauniversity.ac.in, 0009-0005-3854-8324

²ASSISTANT PROFESSOR, DEPARTMENT OF PHARMACY, KALINGA UNIVERSITY, RAIPUR, INDIA.
ku.nainabhoyar@kalingauniversity.ac.in, 0009-0000-0999-8741

³PROFESSOR, NEW DELHI INSTITUTE OF MANAGEMENT, NEW DELHI, INDIA., E-MAIL: monica.verma@ndimdelhi.org, <https://orcid.org/0000-0003-2789-1117>

Abstract

Cancer relapse has long been a deadly issue, and despite advances in oncology, there are currently no effective ways to stop it. The main cause of cancer recurrence is the emergence of treatment resistance. Changes in the therapeutic targets lead to a complex process known as resistance to anticancer therapy. New approaches to fighting drug resistance are made possible by developments in proteomics, DNA microarray, and customized drugs. Despite the rapid discovery of novel chemotherapy drugs, no effective chemotherapy agent has been found to target advanced cancer stages, such as invasion and metastasis. Multi-drug resistance, apoptotic suppression, changes in drug metabolism, pharmacological and epigenetic targets, improving DNA repair, and gene amplification are some of the reasons that might lead to drug resistance in cancer. This review outlined the processes of cancer medication resistance and the reasons why typical chemotherapy therapies are ineffective for different forms of cancer.

Keywords: apoptosis suppression, cancer cell, drug metabolism, chemotherapy

1. INTRODUCTION

In order to establish a new treatment regimen or increase the effectiveness of the current conventional therapy, a lot of study has been conducted in this area during the last ten years. A secondary tumor may be observed in a nearby or distant organ location, or the same organ site may experience this relapse [2]. Additionally, the spread of cancer is largely unpredictable and depends on factors such as the tumor's location, nature, and various phases. Around the world, a great deal of research is being conducted to learn more about how cancer spreads, the mechanisms underlying relapses, and how to prevent them [4]. But realistically speaking, it hasn't helped, as evidenced by the 5-year survival rate of those with metastatic cancer.

One major obstacle to the prognosis and treatment of ovarian cancer, a common cancer in the field of gynecology, is the emergence of chemotherapeutic drug resistance [1] [11]. Interestingly, our results show a substantial correlation between oxidative phosphorylation pathways and EPC medication resistance [6]. Subpopulation and temporal trajectory analysis are then used to confirm EPCs subpopulation C0's intermediate position [3]. Ovarian cancer is the most prevalent and severe of the gynecological cancers, and its frequency has been increasing worldwide in recent years [8]. Since early identification by non-invasive procedures is challenging due to the lack of distinct early indications, up to 70% of women with ovarian cancer acquire a diagnosis at an advanced stage [16].




Figure 1: Drug resistance in cancer

We created a nomogram using the rms software that contained patient age and ethnicity information in order to evaluate the prognosis of patients with ovarian cancer [13]. ROC curves and overall survival (OS) data were used to validate the prognostic model

2. SYSTEM IMPLEMENTATION -

The top three pathways were chosen for further investigation, and we looked into how they were expressed in UMAP representations as well as how they related to drug sensitivity, cell stage, and clusters of ovarian cancer [7]. We performed pseudo-time analysis to examine the evolution and transition of EPC subpopulations. We estimated each subpopulation of EPCs' relative differentiation state using the R program Cytotrace [10]. We classified different EPC subpopulations based on the relative developing time, which we computed using the R tool Monocle [14]. Based on their sorting order, these cells were loosely divided into three phases. Within each cell subpopulation, we investigated how the proportions of cells varied across these three time periods [12].




Figure 2: Drug resistance

After classifying the gene sets into distinct categories according to their temporal expression patterns, we investigated enriched routes connecting them. We investigated the temporal change in the expression of subpopulation-relevant genes, particularly those linked to cell stemness. [9].

4. Results and discussion

Additionally, because the medications are transported by the blood system, their ability to penetrate the tumor's core is diminished. Factors such as the rate of diffusion through tissue and the comparatively wide intercapillary distance in comparison to normal tissue control the distribution of these medications [15].



Figure 3: Drug resistance in bacteria

To sum up, in order to prevent recurrence, an effective DDS that gets past all of these obstacles and targets the resistant cancer cells is required. Recently, nanotechnology has drawn interest as a potential remedy.

Table 1: KMO and Bartlett's Test

Factors	Extraction Sums of Squared Loadings			Rotation Sums of Squared Loadings		
	Total	% of Variance	Cumulative %	Total	% of Variance	Cumulative %
What is the impact of social determinants on health disparities, and how do these disparities vary across different populations?	3.017	33.522	33.522	2.864	31.819	31.819
Can social determinants predict public health outcomes, and if so, which determinants are most strongly associated with these outcomes?	2.005	22.274	55.796	2.016	22.401	54.220
How do social determinants interact with each other to influence public health outcomes?	1.153	12.816	68.612	1.295	14.391	68.612

Furthermore, the stability and specificity of the nanoparticles can be described. Additionally, poor lymphatic drainage and leaky blood arteries in solid tumors facilitate the distribution of these nanoparticles. It is possible to create nanoparticles that include anti-cancer drugs and compounds that block the transport system on their surface in order to regulate the efflux by the transport proteins.




Figure 4: Ovarian cancer drug resistance

Tumorigenesis may result from abnormalities in these stages. Using cell staging in conjunction with our results, we observed that the EPCs cluster had a substantial concentration of G2M and S stages.

Table 2: Variance Explained

Factor	Initial Eigenvalues		
	Total	% of Variance	Cumulative %
How do quantitative measures of social determinants (e.g., census data) align with qualitative accounts of individuals' experiences with these determinants?	3.236	35.957	35.957
Can qualitative findings on the social and cultural contexts of social determinants inform the development of quantitative measures and models?	2.349	26.102	62.058
How can mixed-methods approaches be used to evaluate the effectiveness of interventions addressing social determinants and public health disparities?	1.361	15.120	77.179
What effects do mixed-methods findings have on practices and policies meant to lessen public health disparities?	.766	8.515	85.694
How can the intricate relationships between socioeconomic determinants and public health outcomes be found and addressed using mixed-methods research?	.464	5.160	90.854
What effects do social determinants have on people's health and well-being, and how do communities and individuals feel this?	.339	3.772	94.626
What are the social and cultural contexts in which social determinants operate, and how do these contexts influence health outcomes?	.275	3.060	97.687
How do social determinants affect access to healthcare and health-promoting resources, and what are the consequences for health disparities?	.137	1.522	99.209
What viewpoints and experiences do legislators and healthcare professionals have on the part social determinants play in public health disparities?	.071	.791	100.000

This implies that EPCs have stronger cellular activity and are more resistant to therapy, and there might be some underlying relationships between these traits. Additionally, we used G2M.Score and Score to validate our results, which revealed that EPCs scored much higher than. EPCs showed much higher scores when we looked at the quantity and kinds of DNA replications across various cell groupings. This could be connected to tumor cells' strong ability to proliferate.

5. CONCLUSION

Furthermore, we developed an ovarian cancer prediction model that highlights the potential importance of the Oxidative Phosphorylation pathway and the high-risk gene RPL23 as critical targets for ovarian cancer treatment and drug resistance. In summary, our findings open the door for further research by revealing new processes linked to medication resistance in ovarian cancer. They also aid in the development of a novel and useful predictive model and

offer an additional possible target for ovarian cancer treatment. One significant shortcoming in the current analysis is the lack of integrated omics data, such as proteomics, ATAC-seq, or metabolomics. This restriction emphasizes the necessity of conducting more thorough multi-omics research in the future to improve the breadth and reliability of our findings.

REFERENCE

1. Wu, Qiong, Zhiping Yang, Yongzhan Nie, Yongquan Shi, and Daiming Fan. "Multi-drug resistance in cancer chemotherapeutics: mechanisms and lab approaches." *Cancer letters* 347, no. 2 (2014): 159-166.
2. Kavitha, M. (2023). Beamforming techniques for optimizing massive MIMO and spatial multiplexing. *National Journal of RF Engineering and Wireless Communication*, 1(1), 30-38. <https://doi.org/10.31838/RFMW/01.01.04>
3. Chen, Junsong, Jing Wang, Yunxia Zhang, Dengyu Chen, Cuiping Yang, Cai Kai, Xiaoying Wang, Fangfang Shi, and Jun Dou. "Observation of ovarian cancer stem cell behavior and investigation of potential mechanisms of drug resistance in three-dimensional cell culture." *Journal of bioscience and bioengineering* 118, no. 2 (2014): 214-222.
4. Sudhakar, R., Rajakumari, J., Poornima, S., & Ramya, V. (2019). A security threats and authentication approaches in wireless sensor networks. *International Journal of Communication and Computer Technologies*, 7(2), 1-3.
5. Housman, Genevieve, Shannon Byler, Sarah Heerboth, Karolina Lapinska, McKenna Longacre, Nicole Snyder, and Sibaji Sarkar. "Drug resistance in cancer: an overview." *Cancers* 6, no. 3 (2014): 1769-1792.
6. Snousi, H. M., Aleej, F. A., Bara, M. F., & Alkilany, A. (2022). ADC: Novel Methodology for Code Converter Application for Data Processing. *Journal of VLSI Circuits and Systems*, 4(2), 46–56. <https://doi.org/10.31838/jvcs/04.02.07>
7. Haider, Tanweer, Vikas Pandey, Nagma Banjare, Prem N. Gupta, and Vandana Soni. "Drug resistance in cancer: mechanisms and tackling strategies." *Pharmacological Reports* 72, no. 5 (2020): 1125-1151.
8. Sari, P. K., Trianasari, N., & Prasetyo, A. (2025). Investigating the Main Factors Affecting Healthcare Workers' Information Security Behaviors: An Empirical Study in Indonesia. *Journal of Internet Services and Information Security*, 15(1), 1-15. <https://doi.org/10.58346/JISIS.2025.11.001>
9. Gillet, Jean-Pierre, Anna Maria Calcagno, Sudhir Varma, Miguel Marino, Lisa J. Green, Meena I. Vora, Chirayu Patel et al. "Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance." *Proceedings of the National Academy of Sciences* 108, no. 46 (2011): 18708-18713.
10. Naveen, A., Jeena Jacob, I., & Mandava, A. K. (2025). Student Engagement Analysis using Bi-Up Sampling Feature Pyramid Network with Inter Cross Coordinate Self Attention. *Journal of Wireless Mobile Networks, Ubiquitous Computing, and Dependable Applications*, 16(1), 134-153. <https://doi.org/10.58346/JOWUA.2025.11.008>
11. Bukowski, Karol, Mateusz Kciuk, and Renata Kontek. "Mechanisms of multidrug resistance in cancer chemotherapy." *International journal of molecular sciences* 21, no. 9 (2020): 3233.
12. Younis, A. A., & Alchalabi, A. S. (2025). The Effect of Acidic Environment on Ion Release and Interfacial Adaptation of Two Bioceramic Sealers. *Natural and Engineering Sciences*, 10(1), 41-55. <https://orcid.org/10.28978/nesciences.1611242>
13. Wang, Xuan, Haiyun Zhang, and Xiaozhuo Chen. "Drug resistance and combating drug resistance in cancer." *Cancer drug resistance* 2, no. 2 (2019): 141.
14. Mansoori, Behzad, Ali Mohammadi, Sadaf Davudian, Solmaz Shirjang, and Behzad Baradaran. "The different mechanisms of cancer drug resistance: a brief review." *Advanced pharmaceutical bulletin* 7, no. 3 (2017): 339.
15. Longley, D. B., and P. G. Johnston. "Molecular mechanisms of drug resistance." *The Journal of Pathology: A Journal of the Pathological Society of Great Britain and Ireland* 205, no. 2 (2005): 275-292.
16. PR Xavier, Cristina, Milica Pesic, and M. Helena Vasconcelos. "Understanding cancer drug resistance by developing and studying resistant cell line models." *Current cancer drug targets* 16, no. 3 (2016): 226-237.
17. Sadulla, S. (2024). Techniques and applications for adaptive resource management in reconfigurable computing. *SCCTS Transactions on Reconfigurable Computing*, 1(1), 6-10. <https://doi.org/10.31838/RCC/01.01.02>
18. Thoi, N. T. (2025). Nanoparticle applications revolutionizing chemical processes. *Innovative Reviews in Engineering and Science*, 2(1), 13-21. <https://doi.org/10.31838/INES/02.01.02>

19. Udhayakumar, A., Ramya, K. C., Vijayakumar, P., Sheeba Rani, S., Balamanikandan, A., & Saranya, K. (2024). Reversible Vedic Direct Flag Divider in Key Generation of RSA Cryptography. *Journal of VLSI Circuits and Systems*, 6(2), 75–83. <https://doi.org/10.31838/jvcs/06.02.08>
20. Kavitha, M. (2024). Design and performance analysis of a wideband MIMO antenna array for 5G millimeter-wave applications. *National Journal of RF Circuits and Wireless Systems*, 1(1), 1–10.
21. Surendar, A. (2025). Lightweight CNN architecture for real-time image super-resolution in edge devices. *National Journal of Signal and Image Processing*, 1(1), 1–8.
22. Sindhu, S. (2025). Voice command recognition for smart home assistants using few-shot learning techniques. *National Journal of Speech and Audio Processing*, 1(1), 22–29.
23. Prabhakar, C. P. (2024). Digital twin-based optimization models for intelligent industrial systems. *Electronics, Communications, and Computing Summit*, 2(3), 9–17.